Navigation Links
Pharma's Premier EPI Database Launches New Forecast Period and Disease Indications
Date:5/7/2009

Rich Data Set and Easy-to-Use Web Interface Allows Users to Manipulate Data to Create Custom Epidemiological Projections

PatientBase Also Offers Treatable Pools for Its Cancer Indications

WALTHAM, Mass., May 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, announces the completion of PatientBase's forecast period and disease indication updates. The forecast period now reflects 2008 to 2018 data. PatientBase is the premier epidemiology database for the pharmaceutical industry, providing complete coverage of more than 140 disease indications including over 711 patient populations across the G7 pharmaceutical markets (U.S., France, Germany, Italy, Spain, United Kingdom and Japan).

"In response to our clients' needs we are continuously working on updating PatientBase," stated Amanda Wilson, epidemiologist and product manager at Decision Resources. "Its rich data set and easy-to-use Web interface allows our clients to focus on the age cohort, country, disease subtype (including comorbidity), disease subpopulation segment of interest or specific years to meet their unique needs and research objectives."

PatientBase also offers treatable pools for its cancer indications. Treatable pools can be used for greater accuracy in forecasting and sizing a cancer market by taking into account both relevant patient populations and patient populations by stages.

For a complete list of updated indications, please contact Natalia Morales at nmorales@dresources.com or Elizabeth Marshall at

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Pharmasset to Present at Two Upcoming Investor Conferences
2. Pharmasset to Present at Two Upcoming Investor Conferences
3. ePharmaSolutions Adds Several Industry Clinicians to its Rater Certification and Data Monitoring Department
4. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
5. Parkland Health & Hospital System Rolls Out Innovations PharmASSIST Technology Platform Across Nine Pharmacy Sites
6. PharmaSmart International, Inc. Redefines Blood Pressure Management through Technology and Pharmacy Focused Patient Services
7. Pharmasset to Webcast an Investor Event from the AASLD Meeting
8. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
9. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
10. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
11. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks 2Health News:Physical Therapist, Money Launderer and Patient Recruiter Plead Guilty in Connection With Multiple Detroit Health Care Fraud Schemes 2Health News:Physical Therapist, Money Launderer and Patient Recruiter Plead Guilty in Connection With Multiple Detroit Health Care Fraud Schemes 3Health News:Physical Therapist, Money Launderer and Patient Recruiter Plead Guilty in Connection With Multiple Detroit Health Care Fraud Schemes 4Health News:Fertility Fact vs. Fiction: Women Recognizing Age as a Major Obstacle 2Health News:Fertility Fact vs. Fiction: Women Recognizing Age as a Major Obstacle 3Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 3Health News:Kaiser Permanente Gives $5 Million to Children's Healthcare of Atlanta 2Health News:Kaiser Permanente Gives $5 Million to Children's Healthcare of Atlanta 3
Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10The Forsyth Institute receives the William J Gies Award for outstanding achievement 62358 1The Forsyth Institute receives the William J Gies Award for outstanding achievement 62358 2Are the effects of pornography negligible 3F 62355 1Are the effects of pornography negligible 3F 62355 2Tumor attacking virus strikes with one two punch 10941 1Tumor attacking virus strikes with one two punch 10941 2